Pre-Congress Symposium 3
Radiopharmacy + Oncology & Theraonostics + Dosimetry Committee
Saturday, October 12, 09:00-12:00

Session Title
Alpha Therapy - Practical Aspects on Chemistry and Applications

Chairpersons
Meltem Ocak (Istanbul, Turkey)
Frank Bruchertseifer (Karlsruhe, Germany)

Programme
09:00 - 09:25 Frank Bruchertseifer (Karlsruhe, Germany): An Overview of Production and Radiochemistry of Alpha-Emitting Radionuclides
09:25 - 09:50 Søren Holm (Copenhagen, Denmark): Safe Handling of Alpha-Emitting Radionuclides During Preparation and Application of Radiopharmaceuticals
09:50 - 10:15 Martina Benesova (Heidelberg, Germany): Stability of Alpha-Emitting Radiopharmaceuticals - Impact on TATs

10:15 - 10:45 Coffee Break
10:45 - 11:05 Nicolas Chouin (Nantes, France): Recoil Effect and its Impact on TATs Dosimetry
11:05 - 11:25 Sandra Heskamp (Nijmegen, Netherlands): Antibody Derivatives as a Vehicle for TAT - Advantages, Disadvantages, Future Prospects
11:25 - 11:45 Matthias Miederer (Mainz, Germany): Future Directions for Targeted Alpha Therapy Beyond Prostate Cancer
11:45 - 12:00 Discussion

Educational Objectives
1. General information on production, radiochemistry and safe handling of alpha-emitting radionuclides
2. General information on stability of alpha-emitting radiopharmaceuticals and impacts on TAT dosimetry

Summary
In this symposium practical aspects on chemistry and applications of targeted alpha therapy (TAT) included production, radiochemistry and safe handling of alpha emitting radionuclides & radiopharmaceuticals will be discussed. A state-of-the-art overview of the development of alpha radiopharmaceuticals and effects of their stabilities on dosimetry will be covered. Furthermore, current developments and future directions in TAT beyond prostate cancer will be reviewed from clinical perspective.

Key Words
Alpha-emitting radionuclides & radiopharmaceuticals, stability, dosimetry